{"id":958,"date":"2015-03-20T10:11:39","date_gmt":"2015-03-20T01:11:39","guid":{"rendered":"http:\/\/misterx95.myds.me\/?p=958"},"modified":"2015-03-20T10:11:40","modified_gmt":"2015-03-20T01:11:40","slug":"journal-club-2015-3-20","status":"publish","type":"post","link":"https:\/\/misterx95.myds.me\/wordpress\/?p=958","title":{"rendered":"Journal club 2015.3.20"},"content":{"rendered":"<h1><div class=\"attachments\"><dl class=\"attachments attachments-medium\">\r\n<dt class=\"icon\">\r\n\t<a title=\"Akiyama et al_2015_Nalfurafine Suppresses Pruritogen- and Touch-evoked Scratching Behavior in\" href=\"https:\/\/misterx95.myds.me\/wordpress\/?p=958&aid=959&sa=0\" rel=\"nofollow\">\r\n\t\t<img src=\"https:\/\/misterx95.myds.me\/wordpress\/wp-content\/plugins\/eg-attachments\/img\/flags\/document.png\" width=\"32\" height=\"32\"  alt=\"Akiyama et al_2015_Nalfurafine Suppresses Pruritogen- and Touch-evoked Scratching Behavior in\" \/>\r\n\t<\/a>\r\n<\/dt>\r\n<dd class=\"caption\">\r\n\t<strong>Filename<\/strong> : <a title=\"Akiyama et al_2015_Nalfurafine Suppresses Pruritogen- and Touch-evoked Scratching Behavior in\" href=\"https:\/\/misterx95.myds.me\/wordpress\/?p=958&aid=959&sa=0\" rel=\"nofollow\">akiyama-et-al_2015_nalfurafine-suppresses-pruritogen-and-touch-evoked-scratching-behavior-in.pdf<\/a> (489 KB)\r\n\t<br>\r\n\t<strong>Caption<\/strong> : \r\n<\/dd>\r\n<\/dl><p><\/p><\/div><\/h1>\n<h1><span class=\"highlight\">Nalfurafine<\/span> <span class=\"highlight\">suppresses<\/span> <span class=\"highlight\">pruritogen<\/span>&#8211; and <span class=\"highlight\">touch-evoked<\/span> <span class=\"highlight\">scratching<\/span> <span class=\"highlight\">behavior<\/span> in <span class=\"highlight\">models<\/span> of <span class=\"highlight\">acute<\/span> and <span class=\"highlight\">chronic<\/span> <span class=\"highlight\">itch<\/span>in <span class=\"highlight\">mice<\/span>.<\/h1>\n<div class=\"auths\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Akiyama%20T%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24890341\">Akiyama T<\/a><sup>1<\/sup>, <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Carstens%20MI%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24890341\">Carstens MI<\/a>, <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Piecha%20D%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24890341\">Piecha D<\/a>, <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Steppan%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24890341\">Steppan S<\/a>, <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Carstens%20E%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24890341\">Carstens E<\/a>.<\/div>\n<div class=\"afflist\">\n<h3><a class=\"jig-ncbitoggler ui-widget ui-ncbitoggler\" title=\"Open\/close author information list\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Nalfurafine%20Suppresses%20Pruritogen-%20and%20Touch-evoked%20Scratching%20Behavior%20in%20Models%20of%20Acute%20and%20Chronic%20Itch%20in%20Mice#\"><span class=\"ui-ncbitoggler-master-text\">Author information<\/span><\/a><\/h3>\n<div class=\"ui-helper-reset\"><\/div>\n<\/div>\n<div class=\"abstr\">\n<h3>Abstract<\/h3>\n<div class=\"\">\n<p>The kappa-opioid agonist, <span class=\"highlight\">nalfurafine<\/span>, has been approved in Japan for treatment of <span class=\"highlight\">itch<\/span> in patients with <span class=\"highlight\">chronic<\/span> kidney disease. We presently investigated if systemic administration of <span class=\"highlight\">nalfurafine<\/span> inhibited ongoing or <span class=\"highlight\">touch-evoked<\/span> <span class=\"highlight\">scratching<\/span> <span class=\"highlight\">behavior<\/span> (alloknesis) following <span class=\"highlight\">acute<\/span>intradermal injection of histamine or the non-histaminergic <span class=\"highlight\">itch<\/span> mediator, chloroquine, in <span class=\"highlight\">mice<\/span>. We also investigated if <span class=\"highlight\">nalfurafine<\/span> suppressed spontaneous or <span class=\"highlight\">touch-evoked<\/span> <span class=\"highlight\">scratching<\/span> in an experimental model of <span class=\"highlight\">chronic<\/span> dry skin <span class=\"highlight\">itch<\/span>. <span class=\"highlight\">Nalfurafine<\/span> reduced <span class=\"highlight\">scratching<\/span> evoked by histamine and chloroquine. Following <span class=\"highlight\">acute<\/span> histamine, but not chloroquine, low-threshold mechanical stimuli reliably elicited directed hindlimb <span class=\"highlight\">scratching<\/span><span class=\"highlight\">behavior<\/span>, which was significantly attenuated by <span class=\"highlight\">nalfurafine<\/span>. In <span class=\"highlight\">mice<\/span> with experimental dry skin, <span class=\"highlight\">nalfurafine<\/span> abolished spontaneous <span class=\"highlight\">scratching<\/span> but had no effect on alloknesis. <span class=\"highlight\">Nalfurafine<\/span> thus appears to be a promising treatment for <span class=\"highlight\">acute<\/span> <span class=\"highlight\">itch<\/span> as well as ongoing <span class=\"highlight\">itch<\/span> of dry skin.<\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nalfurafine suppresses pruritogen&#8211; and touch-evoked scratching behavior in models of acute and chronic itchin mice. Akiyama T1, Carstens MI, Piecha D, Steppan S, Carstens E. Author information Abstract The kappa-opioid agonist, nalfurafine, has been approved in Japan for treatment of itch in patients with chronic kidney disease. We presently investigated if systemic administration of nalfurafine [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}}},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/misterx95.myds.me\/wordpress\/index.php?rest_route=\/wp\/v2\/posts\/958"}],"collection":[{"href":"https:\/\/misterx95.myds.me\/wordpress\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/misterx95.myds.me\/wordpress\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/misterx95.myds.me\/wordpress\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/misterx95.myds.me\/wordpress\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=958"}],"version-history":[{"count":2,"href":"https:\/\/misterx95.myds.me\/wordpress\/index.php?rest_route=\/wp\/v2\/posts\/958\/revisions"}],"predecessor-version":[{"id":961,"href":"https:\/\/misterx95.myds.me\/wordpress\/index.php?rest_route=\/wp\/v2\/posts\/958\/revisions\/961"}],"wp:attachment":[{"href":"https:\/\/misterx95.myds.me\/wordpress\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=958"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/misterx95.myds.me\/wordpress\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=958"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/misterx95.myds.me\/wordpress\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=958"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}